Factors Determining Dissemination of Results and Uptake of Genetic Testing in Families with Known <i>BRCA1/2</i> Mutations
Esmé Finlay(University of Pennsylvania), Susan M. Domchek(University City Science Center), Barbara Weber(University of St.Gallen), Katrina Armstrong(Columbia University), Katherine G. Evans(University of Pennsylvania), Katherine L. Nathanson(Translational Therapeutics (United States)), Timothy R. Rebbeck(Dana-Farber Cancer Institute), E. Burlingame(University of Pennsylvania), Jill E. Stopfer(University of Pennsylvania)
Cited by 168
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981